Timothy M. Clay, Ph.D.
Recent Publications

Sun B,Kulis MD,Young SP,Hobeika AC,Li S,Bird A,Zhang H,Li Y,Clay TM,Burks W,Kishnani PS,Koeberl DD. Immunomodulatory Gene Therapy Prevents Antibody Formation and Lethal Hypersensitivity Reactions in Murine Pompe Disease.,8/18/2009, (-) - Molecular therapy : the journal of the American Society of Gene Therapy Abstract [More ...] Osada T,Woo CY,McKinney M,Yang XY,Lei G,Labreche HG,Hartman ZC,Niedzwiecki D,Chao N,Amalfitano A,Morse MA,Lyerly HK,Clay TM. Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.,4/15/2009, (2789-96) - Clinical cancer research : an official journal of the American Association for Cancer Research Abstract [More ...] Osada T,Yang XY,Hartman ZC,Glass O,Hodges BL,Niedzwiecki D,Morse MA,Lyerly HK,Amalfitano A,Clay TM. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.,2/20/2009, (-) - Cancer gene therapy Abstract [More ...] Morse MA,Hobeika AC,Osada T,Serra D,Niedzwiecki D,Lyerly HK,Clay TM. Depletion of human regulatory T cells specifically enhances antigen specific immune responses to cancer vaccines.,6/2/2008, (-) - Blood Abstract [More ...] Maecker HT,Hassler J,Payne JK,Summers A,Comatas K,Ghanayem M,Morse MA,Clay TM,Lyerly HK,Bhatia S,Ghanekar SA,Maino VC,Delarosa C,Disis ML. Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides.,3/17/2008, (9) - BMC immunology Abstract [More ...] Hartman ZC,Appledorn DM,Serra D,Glass O,Mendelson TB,Clay TM,Amalfitano A. Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system.,2/14/2008, (-) - Virology Abstract [More ...] Morse MA,Hobeika A,Osada T,Niedzwiecki D,Marcom PK,Blackwell KL,Anders C,Devi GR,Lyerly HK,Clay TM. Long Term Disease-Free Survival and T Cell and Antibody Responses in Women with High-Risk HER2+ Breast Cancer Following Vaccination Against HER2+,9/6/2007, (42) - Journal of translational medicine Abstract [More ...] Janetzki S,Panageas KS,Ben-Porat L,Boyer J,Britten CM,Clay TM,Kalos M,Maecker HT,Romero P,Yuan J,Martin Kast W,Hoos A. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI).,8/25/2007, (-) - Cancer immunology, immunotherapy : CII Abstract [More ...] Murad YM,Clay TM,Lyerly HK,Morse MA. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.,8/1/2007, (1257-66) - Expert opinion on biological therapy Abstract [More ...] Langer LF,Clay TM,Morse MA. Update on anti-CTLA-4 antibodies in clinical trials.,8/1/2007, (1245-56) - Expert opinion on biological therapy Abstract [More ...]

---

NOTE: For more publications on this researcher, please visit Pubmed - A service of the National Library of Medicine and the National Institutes of Health.